SystImmune, Inc., a clinical-stage biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1. This antibody-drug conjugate (ADC) incorporates a novel linker and payload technology and is poised to enter Phase 1 clinical trials for the treatment of advanced or metastatic solid tumors. The IND clearance marks a significant advancement for SystImmune's pipeline of innovative therapeutic candidates.
The Phase 1 clinical trial, designated BL‑M17D1-ST-101, will primarily evaluate the safety and tolerability of BL-M17D1. Secondary endpoints include assessing the pharmacokinetics and preliminary efficacy of the ADC in patients with advanced or metastatic solid tumors. The trial will be conducted in the United States.
Novel ADC Technology
BL-M17D1 is developed using SystImmune's next-generation linker and payload technology. This innovative approach aims to enhance the therapeutic potential of ADCs, potentially leading to improved clinical outcomes for patients. The specific details of the linker and payload technology were not disclosed.
Executive Perspective
Dr. Jie D’Elia, Chief Executive Officer of SystImmune, stated, “Our mission at SystImmune is to bring therapies that can provide transformative clinical benefit to patients. As BL-M17D1 is developed using our next generation linker and payload technology, the initiation of clinical development for BL-M17D1 demonstrates our ability to continue to innovate in the ADC space and bring potentially best-in-class products to patients.”
About SystImmune
SystImmune is a biopharmaceutical company specializing in the development of cancer treatments. Their focus includes bi-specific, multi-specific antibodies, and ADCs. The company has multiple assets in clinical trials targeting both solid tumors and hematologic malignancies. In addition to its clinical programs, SystImmune has a robust preclinical pipeline focused on novel cancer therapeutics.
